We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Dose Escalation of OXi4503 as Single Agent and Combination With Cytarabine w/Subsequent Ph 2 Cohorts for AML and MDS (AML)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02576301
Recruitment Status : Recruiting
First Posted : October 15, 2015
Last Update Posted : September 25, 2017
Information provided by (Responsible Party):
Mateon Therapeutics

No Study Results Posted on ClinicalTrials.gov for this Study
  Recruitment Status : Recruiting
  Estimated Primary Completion Date : October 2017
  Estimated Study Completion Date : October 2020